Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin A in allogeneic haematopoietic stem cell transplantation recipients

References

• Arora, M., et al., 2016. Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplant, 22 (3), 449–455.
   PubMed Web of Science ®Google Scholar
• Atiq, F., et al., 2018. Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals. European journal of clinical pharmacology, 74 (6), 767–773.
   PubMed Web of Science ®Google Scholar
• Chen, X., et al., 2012. Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6. PLOS one, 7 (6), e38495.
   PubMed Web of Science ®Google Scholar
• Ciurea, S.O., et al., 2019. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood, 134 (Supplement_1), 42–42.
   Web of Science ®Google Scholar
• Cvetkovic, M., et al., 2017. Effect of age and allele variants of CYP3A5, CYP3A4, and POR genes on the pharmacokinetics of cyclosporin A in pediatric renal transplant recipients from Serbia. Therapeutic drug monitoring, 39 (6), 589–595.
   PubMed Web of Science ®Google Scholar
• Elens, L., et al., 2014. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Therapeutic drug monitoring, 36 (1), 1.
   PubMed Web of Science ®Google Scholar
• Gu, X., et al., 2006. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. Journal of biological chemistry., 281 (26), 17882–17889.
   PubMed Web of Science ®Google Scholar
• Hesselink, D.A., et al., 2008. A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Pharmacogenomics, 9 (6), 783–789.
   PubMed Web of Science ®Google Scholar
• Hu, Y.F., et al., 2007. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica, 37 (3), 315–327.
   PubMed Web of Science ®Google Scholar
• Huang, B., et al., 2020. Comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis after allogeneic hematopoietic cell transplantation. Transplantation, 104 (2), 428–436.
   PubMed Web of Science ®Google Scholar
• Jordán De Luna, C., et al., 2011. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. Transplantation proceedings, 43 (6), 2241–2243.
   PubMed Web of Science ®Google Scholar
• Lunde, I., et al., 2014. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. European journal of clinical pharmacology, 70 (6), 685–693.
   PubMed Web of Science ®Google Scholar
• McCune, J.S., and Bemer, M.J., 2016. Pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressants in allogeneic haematopoietic cell transplantation: part I. Clinical pharmacokinetics., 55 (5), 525–550.
   PubMed Web of Science ®Google Scholar
• Oleson, L., et al., 2010. Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica, 40 (2), 146–162.
   PubMed Web of Science ®Google Scholar
• Qiu, X.Y., et al., 2008. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. European journal of clinical pharmacology, 64 (11), 1069–1084.
   PubMed Web of Science ®Google Scholar
• Satwani, P., et al., 2017. A multicenter study of bacterial blood stream infections in pediatric allogeneic hematopoietic cell transplantation recipients: the role of acute gastrointestinal graft-versus-host disease. Biology of blood and marrow transplantation, 23 (4), 642–647.
   PubMed Web of Science ®Google Scholar
• Schirmer, M., et al., 2007. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics, 8 (5), 443–453.
   PubMed Web of Science ®Google Scholar
• Sefidgar, M., et al., 2014. Effect of tumor shape, size, and tissue transport properties on drug delivery to solid tumors. Journal of biological engineering., 8, 12.
   PubMed Web of Science ®Google Scholar
• Shao, B., et al., 2018. Vitamin D pathway gene polymorphisms influenced vitamin D level among pregnant women. Clinical nutrition, 37 (6), 2230–2237.
   PubMed Web of Science ®Google Scholar
• Sharaki, O., et al., 2015. Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. Molecular biology reports, 42 (1), 105–117.
   PubMed Web of Science ®Google Scholar
• Stocker, N., et al., 2019. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation. European journal of haematology, 103 (1), 10–17.
   PubMed Web of Science ®Google Scholar
• Sun, B., et al., 2017. Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients. Pharmacogenomics, 18 (16), 1503–1513.
   PubMed Web of Science ®Google Scholar
• Wang, P., et al., 2015. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy research, 117, 52–57.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2013. Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ACTA Pharmacologica Sinica., 34 (4), 555–560.
   PubMed Web of Science ®Google Scholar
• Zhou, Q., et al., 2005. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. British journal of clinical pharmacology, 59 (4), 415–424.
   PubMed Web of Science ®Google Scholar